Louis de Traverse

At Beo Healthcare, we partner with multiple health professionals to ensure that #alix, our hybrid artificial intelligence, includes the right features and benefit for patients' quality of life. Alix is designed to target multiple diseases, including #cancer We want to thank MD, brain surgeons at CHU de Brest for sharing relevant research publications with us to allow the right developments of Alix, in particular to have a solution that is customized, specific to each individual Extracts from the Abstract ⤵️: " Fatigue is one of the most common adverse effects of cancer that might persist for years after treatment completion in otherwise healthy survivors. Cancer-related fatigue causes disruption in all aspects of quality of life and might be a risk factor of reduced survival. The prevalence and course of fatigue in patients with cancer have been well characterized and there is growing understanding of the underlying biological mechanisms. Inflammation seems to have a key role in fatigue before, during, and after cancer-treatment. However, there is a considerable variability in the presentation of cancer-related fatigue, much of which is not explained by disease-related or treatment-related characteristics" "... a variety of intervention approaches have shown beneficial effects in randomized controlled trials, including physical activity, psychosocial, mind–body, and pharmacological treatments..." #md #hospital #cancer #AI #AIforHealth #Healthcare #Europe #USA #futureofmedicine #physicalactivity #customizedmedecine #patientqualityoflife #brainsurgeon #fatigue #cancerrelatedfatigue Sophie Deniel Yannick GUILLODO Chloé Le Douarin Sullivan Gauville Lucas Morisseau Maxime B'chir Benoît Quero Jean-Luc DUFOUR Mathieu Champenois Yann Le DOUARIN Nature Research Custom Media UCLA MACMILLAN PUBLISHERS INTERNATIONAL LIMITED

8

🔍 France's Medtech sector is at a pivotal moment...In 2023, financial sponsor exits in French healthcare totaled just €141M compared to €1.3B in Germany and €8.1B in the US! Despite its rich history in medical innovation, the lack of local private equity investment is holding back promising companies. France currently accounts for 14% of the European medical device market but lags behind Germany’s 27%. The good news? There’s a backlog of mature French medtech firms generating revenues of €20M to €30M that are ready to scale up, but they need more local growth capital. Upcoming deals, such as Astorg’s stake in Echosens and Theravia’s exit pipeline, highlight the potential waiting to be unlocked. With the new European Commission expected to simplify regulations, the question remains: how can we harness PE support to ensure France's medtech sector thrives? Source : ION Analytics, Med Tech Europe #Healthcare #Medtech #Privateequity #Investments #France ——— I am Alexis - French pharmacist turned entrepreneur. My company BTHT is connecting senior industry experts, ex-payors, and KOLs with consultants and investors in Life Sciences and Healthcare for expert calls and senior advisory. Join 16K+ followers by clicking my name + follow 🔔 Join 1.4K+ subs to my weekly newsletter 💌

19

The next pole of #medtech innovation in Europe! Nextmed Strasbourg in Strasbourg, #grandest, is set to expand.... in number of startups, projects in research, and integration of AI in medical devices. MedTech Europe EIT - European Institute of Innovation and Technology

13

Looking forward to sharing my perspectives and hearing how others are approaching the global VC landscape at this session at #GRIC2024!

19

Proud to have Julian Rozenberg from Agence de l'innovation en santé visit us ! Launched in June 2021 by the President of the Republic as part of the Health Innovation 2030 plan and led by Lise ALTER, the Health Innovation Agency (AIS) is tasked with piloting and coordinating measures to promote innovations with a positive impact on patient health in France. 🎯 12 priority tasks are structured around 5 levers: Anticipating innovations and medical needs to guide public policies. Facilitating, accelerating, and simplifying the journey of an innovation, from its conception to its availability to patients. Supporting innovative project leaders at each stage of their journey. Investing to make France the leading innovative and sovereign European nation in health. Integrating prevention as a pivot for scaling up positive health outcomes for the French population.

56

2 commentaires

🌍Spotlight on Resah Meet our Technical Expert in Healthcare Public Procurement, in charge of leading the Observational Study on European Healthcare & Procurement Environment across 12 Member States! 🔎 Who is the Resah? Resah is a public Central Purchasing Body that leverages the purchasing power of hospitals and nursing homes in France. Resah is the only Central Purchasing Body specialized in both healthcare and medical-social sectors in France. It offers more than 4000 public contracts in all the procurement segments, covering all hospital needs: medical (pharmaceuticals, medical devices, biomedical equipment, PPE…) and non-medical (ICT solutions, catering, energy…), from more than 700 suppliers, including 45% of SMEs. Today the public organization has more than 2100 beneficiaries, including almost all French public and non-for-profit hospitals, nursing homes but also other public organizations like the public health national agency. The procurement volume through Resah’s public contracts was € 2.8 billion in 2023. Resah is one of the key procurement players in the healthcare sector in France and Europe. Resah is the founding member of the EHPPA Association. 🚀 Resah’s Role in PROCURE As the leader of Work Package 2 (WP2), Resah is responsible of the 1st phase of the project, the Observational Study on European Healthcare & Public Procurement Environment, with the collaboration of UPM and 12 Country Leaders from the Member States. ·        Main objective of this part is to get a deep knowledge of the European public procurement landscape ·        After the setting of the Country nodes and the definition of the common means and standardised methodology, guided by Resah, the 12 Country Leaders have collected the information from their respective nodes of healthcare organisations ·        Resah is currently consolidating the data to build the 12 ID Cards including key information from the National healthcare system; the public procurement environment and the Public Procurement practices and Covid impacts per Member States ·        Resah will soon delivery the final report to the European Commission, made of the Study methodology, the 12 ID Cards, the comparative analysis and the final conclusions ·        This Observational Study will constitute useful knowledge resources that organisations from other Regions or Countries can refer to in the future, to better understand the different National Healthcare system and Public Procurement processes and practices across Europe Stay tuned to learn more about the other partners in the consortium and their roles in PROCURE project making healthcare procurement more resilient and efficient across the European Union! #HealthcareInnovation #EU4Health #EUfunded, #HealthUnion, #procureproject #PublicProcurement #ActiveAgeing #EUProjects #PROCURE #Resah #EHPPA

26

Digital Health in France: A Snapshot Over a year after #telemonitoring was officially integrated into France's healthcare system, the digital health market is beginning to take shape. While telemonitoring is making headway, particularly in oncology, digital therapies (#DTx) are struggling to gain a foothold. ✅ Telemonitoring Leading the Way, DTx Lagging Behind France has made notable progress in telemonitoring, with systems like Resilience Pro seeing success, especially in oncology. However, DTx is still facing significant challenges. The sluggish pace is primarily due to stringent requirements for clinical and organizational benefits, coupled with the government’s public health priorities, which tend to favour oncology and mental health (like depression and anxiety) while leaving areas like rehabilitation and chronic disease management behind. ✅ Market Trends: Where Digital Health is Gaining Ground ✔ Telemonitoring Gains Momentum in Oncology: Since June 2023, telemonitoring devices have been reimbursed under the general health coverage system, with cancer monitoring tools showing strong progress (1890 health structures have declared a remote monitoring activity so far). ✔ DTx Adoption Slow: Despite the rise of digital therapies in Europe, France lags behind countries like Germany. Hannes Klöpper has recently posted valuable insight about HelloBetter's struggle to secure reimbursement from Cnedimts. ✅ France vs. Germany France’s strict regulatory landscape contrasts sharply with Germany’s more flexible DiGA program, which allows faster reimbursement for digital health applications. Germany’s approach has fostered a broad range of innovative solutions, while France’s focus remains on specific areas like oncology. This explains why Germany is ahead in DTx adoption. ✅ Navigating the French Market: Key Insights and some advise ✔ Tackle Regulatory Hurdles Head-On: Be ready for a rigorous approval process, particularly for DTx. Early engagement with French authorities and collaboration with local players will definitely help navigate this complex landscape. I would recommend an upfront check-up of your « Market Access Readiness ». Spending that time is gaining a better view on your winning strategy and evaluating your chances more efficiently. ✔ Align with Priority Areas: Products targeting government-prioritized areas like oncology and mental health are more likely to succeed. Keep an eye on evolving health priorities to position your offerings strategically. ✔ Leverage Partnerships and Pilots: Forge alliances with influent French stakeholders and participate in pilot projects like “Article 51” to enhance market entry and boost approval chances. ✔ Plan for Financial Challenges: The path to market in France is costly and time-consuming. Explore alternative business models, such as direct-to-patient sales or partnerships with private insurers, to offset upfront costs.

2

Talking about the key factors investors consider when evaluating a company in healthcare, Arnaud Vincent, Managing Director - Healthcare at Eurazeo, said, "We consider the quality of the revenue, the quality of growth, and the speed to profitability. First, we invest in companies which have high-quality sales and good geographical diversity. Second, we look at the company’s sales cycle, particularly if it's challenging. The last thing is how fast we can achieve profitability." Stay tuned as we are sharing more insightful takeaways from #HBI2024! #eyehealthcare #healthcareconference #HBI #HealthcareInvestment #CEOs #Investors #HealthcareConference #HealthcareIndustry #InvestmentStrategy

64

In Wallonia, innovation in the fight against cancer is at the top of the world, thanks to the presence of leading companies in ATMPs, nuclear medicine, immunotherapy, precision medicine, and proton therapy, supported by exceptional academics and clinicians. Great news for patients—and a prime opportunity for investors to align impact with profit. In 2024, investment focused on cancer, accounting for 39% of total funds raised worldwide 🤯 👉 Read this interesting article by Amel Tounsi and Eric Brandt: https://lnkd.in/ev6nhjUg

15

In Wallonia, innovation in the fight against cancer is at the top of the world, thanks to the presence of leading companies in ATMPs, nuclear medicine, immunotherapy, precision medicine, and proton therapy, supported by exceptional academics and clinicians. Great news for patients—and a prime opportunity for investors to align impact with profit. 👉 Read this interesting article mentioning PDC*line Pharma https://lnkd.in/ev6nhjUg

2

Dear Armin Scheuer Thank you for including me in the discussion on #digitaltransformation. I appreciate the opportunity to provide my perspective on this crucial topic. From my experience, the most critical aspect of #digitaltransformation is the widespread #adoption of #digitaltechnologies across various stakeholders. 💻 Infrustructure adoption📱. Healthcare providers 🏥 must use #HealthInformationSystems (#HIS) with international standards such as #HL7 and #FHIR. Structured data can facilitate the creation of robust datasets for future AI learning and enable interoperability among different Software-as-a-Service (#SaaS) solutions. Hardware for data storage and continuous learning of AI models with security access. 📚 Policy adoption Healthcare authorities and policymakers should be agile and foster an environment conducive to a seamless and secure digital transformation process. With the rapid integration of AI technologies like ChatGPT Google Gemini #Llama, Anthropic, it is imperative to develop transparent and evidence-based AI models. We need to evaluate and determine which AI models will be most beneficial for healthcare applications. 👨‍⚕️ Human adoption. 🤒 Patients and physicians must be aware of and well-educated in the effective use of digital tools such as computers, mobile devices, and wearable devices. Without widespread adoption and proper training among healthcare professionals and patients, the successful implementation of digital transformation initiatives will be challenging. 🔑 I believe that the best adoption with collaboration of all stakeholders will helps improve value-based healthcare to save time, lives and money.

13

1 commentaire

KLEA HOLDING (ex VISIOMED GROUP) : Klea Holding extends the maturity of the Equisafe Bond: Paris, December 6, 2024 KLEA HOLDING (FR0013481835 – ALKLH), a group focused on the acquisition, development and digitalization of companies across multiple sectors, announces the extension of the Equisafe Bond maturity, in agreement with Equisafe's Bondholders. Following a validation by the Equisafe Bondholders at their General Assembly (please refer to the press release dated August 22, 2022 for further details), Klea Holding has signed an amendment to the Equisafe Bond agreement with new terms as follows: * Total due principal revised at € 2 987 620,47 after the payment of interests in August 2024 and a principal repayment of € 700 000 in October 2024 * New maturity extended until March 2027 * Revised interest rate of 11.5% per annum * Installment schedule as described in the table presented below (Installment Schedule) Klea Holding CEO Clement Pacaud said: “We are happy to extend the maturity of the Equisafe Bond until March 2027 and tailor the principal repayments over that period, aligning well with Klea's momentum and the important milestone we steadily reach. We value the support and the trustful relationship with Equisafe and the bondholders since 2022.” About Klea Holding Klea Holding is a group focused on acquiring, developing and digitizing companies in various sectors to maximize their growth and value. Through its "scaling industries of the future" identity, Klea Holding draws on its successful experience in developing Smart Salem, the first network of digitalized medical analysis centers accredited by the Dubai Ministry of Health (DHA) in the United Arab Emirates, and its Smart Health joint venture developed in Saudi Arabia, to extend this entrepreneurial approach to the four corners of the globe. Klea Holding is headquartered in Paris and listed on Euronext Growth (ALKLH). For further information, please visit www.kleaholding.com Investor Relation: Jérôme FABREGUETTES LEIB // +33 1 53 67 36 78 // [email protected] Press Relation: Fatou-Kiné N'DIAYE // +33 1 53 67 36 34 // [email protected] Installment Schedule Date Installment Interest Principal reimbursment Equisafe fees Due Principal 29/08/2024 382 262,16 € 382 262,16 € 0,00 € 0,00 € 3 640 592,00 € 09/10/2024 700 000,00 € 47 028,47 € 652 971,53 € 0,00 € 2 987 620,47 € 31/12/2024 182 028,32 € 78 128,32 € 100 000,00 € 3 900,00 € 2 887 620,47 € 31/01/2025 100 000,00 € 25 751,25 € 70 348,75 € 3 900,00 € 2 817 271,71 € 28/02/2025 100 000,00 € 22 692,54 € 73 407,46 € 3 900,00 € 2 743 864,26 € 30/03/2025 100 000,00 € 23 679,92 € 72 420,08 € 3 900,00 € 2 671 444,18 € 30/04/2025 100 000,00…

1

📢 Research Platform - Towards a healthcare society 🤝 Are you looking to conduct disruptive research on the topic of health? Health as a state of complete physical, mental and social well-being and not the absence of disease or other physical defects. Could this research be performed by an interinstitutional and multidisciplinary consortium of research organizations located in the Brussels-Capital Region? Is the medium-term objective of the project to valorize its results? Find out more about this program here 👇 https://bit.ly/3UM27Jj Deadline : 28 juin 2024 #wefundyourfuture #research #health #healthcare #brussels

6

🧬 Latest Deals in Healthcare & Life Sciences 💼 💼 Extens has acquired a majority stake in Medicore, marking its first investment outside France, as part of its European expansion strategy, focusing on enhancing mental health solutions and EHRs for over 25,000 healthcare professionals. 💰 Kurma Partners has successfully closed €140m in its first closing of Biofund IV, aiming to raise a total of €250m by 2025 for innovative therapeutics investments. 💰 Healius has entered into a binding agreement to sell its Lumus Imaging subsidiary to Affinity Equity Partners for an enterprise value of A$965m (US$669m), enabling Healius to focus on its pathology strategy and enhance customer service and digital technologies. 🤝 Fondo Italiano d'Investimento SGR has invested €10m to acquire a minority stake in Intrauma, a developer of advanced orthopaedic medical devices, to support its growth targets and product expansion. 🇬🇧 Huma has acquired eConsult and launched Huma Workspace, aiming to create a comprehensive digital-first healthcare platform for the NHS. 💰 Asabys Partners has successfully closed its Sabadell Asabys Health Innovation Investments II Fund at €180m, surpassing its target of €150m, to invest in biopharma, medical devices, and digital health companies. 🔬 Bruker Corporation has acquired Dynamic Biosensors, enhancing its biophysical portfolio for biomolecular interaction analysis. 💼 Miura Partners has closed its fourth flagship fund, Miura Fund IV, at its hard cap of €475m, marking a total fundraising of €800m in 2024, with significant investments in family-owned businesses across healthcare, education, and other sectors 🩺 Mölnlycke Health Care has finalized its acquisition of PGF Industry Solutions, the Austrian manufacturer of Granudacyn wound cleansing and moistening solutions. Source : Investors in Healthcare ——— I am Alexis - French pharmacist turned entrepreneur. My company BTHT connects experts with consultants and investors in Life Sciences and Healthcare for expert calls and senior advisory. For more content like this 👇 Join 15K+ followers by clicking my name + follow 🔔 Join 1.4K+ subscribers to my weekly newsletter 💌

25

2 commentaires

We previously discussed #QALYs in #HealthEconomicEvaluations ? But to calculate #QALYs, you need #utilities 😀 ! These are subjective values, and estimate the perception of #QualityOfLife at a certain point in time. This video describes the main methods to derive such estimates. #TTO #VAS #SG, #EQ5D, etc... these are key words you may have herd before. Wanna understand them better? Of note : all the links we share contain a summary PDF you can download, summarizing the video, so don't hesitate ! https://lnkd.in/e-7jxrfa

61

The European Innovation Council and SMEs Executive Agency (EISMEA) Accelerator, which supports the most disruptive innovators, is one of Europe’s most competitive funding instruments, with a success rate below 5%. Last week, we learned that one of our clients, active within the Medtech vertical, received the GO for Phase II. We’ll soon start working on preparing the #EICAccelerator Phase II proposal for the March 2025 cut-off date. It's an intensive process but incredibly rewarding. As we navigate this journey, the focus remains on backing impact innovators, securing the necessary funding, and ensuring their innovation scales to new heights! #followfundingloop #EICAccelerator #medtech #EUfunding #fundinginnovation If you’re interested in applying for funding, write to us! https://lnkd.in/eSFy2qZB

13

2 commentaires

🧑‍⚕️ 'Our home #nurses exchange information about #patients and make mutual decisions via Doctolib Siilo. It is crucial that they can communicate with each other securely, especially as we handle sensitive information subject to #GDPR legislation', says Julie Vanhoof, Business Unit Manager at OptiCare Thuisverpleging. Read the full interview with Julie about the use of Doctolib Siilo within their organisation (article in Dutch 🇳🇱🇧🇪) >> https://ow.ly/gwIL50RQyoJ #healthcare #ehealth #medicine #gezondheidszorg #zorg

19

3 commentaires

💊 DeepTech Disruption in Healthcare: France-Japan Synergies for a Healthier Future On December 5th, the Demo Night NEDO will spotlight groundbreaking Japanese DeepTech startups, driving innovation in Healthcare. Organized by WILCO and SINEORA for NEDO, this exclusive event is your opportunity to witness disruptive solutions reshaping the future of health. 🎯 Spotlight on Healthcare Innovators: Masayasu Tanase, CEO of ARCS – Enhancing IVF success rates through AI-driven sperm analysis. Their solution evaluates sperm mobility, morphology, and DNA damage, ensuring better embryo selection and improving fertility outcomes. 👤Yuki Miyazaki, CFO of CATE Inc. – Transforming cardiac rehabilitation with an AI-powered medical app for at-home use, improving recovery experiences for patients worldwide. 👤Kazuyuki Doi, Business Development at 株式会社InnoJin – Introducing a non-invasive mobile diagnostic app for dry eye disease. This technology enables quick and easy diagnostics anywhere, supporting accessible and effective eye care. 👤Lucas Mixich, Business Development at Fermelanta, Inc. – Transforming supply chains with synthetic biology to produce rare plant-based ingredients. Sustainable, affordable, and consistent alternative  solutions for sourcing active ingredients. 💡These startups are at the forefront of DeepTech innovation, tackling critical challenges in fertility, diagnostics, cardiac care, and nutrition to create a healthier future. 🗓️ Event Details: When: Thursday, December 5, 2024, 6:00 PM - 9:00 PM Where: E-Spot, 150 rue de Rivoli, Paris ✨ Agenda of the evening  Roundtable on France-Japan Synergies: Explore collaborative opportunities in health innovation. DeepTech Startup Pitches: Discover disruptive healthcare solutions ready to transform European markets. Networking Cocktail: Meet healthcare leaders, innovators, and cross-border collaborators. 🔗 Register here: [https://lnkd.in/edKWSzhi] Join us to explore how DeepTech excellence and France-Japan collaboration are driving innovation in Healthcare.

15

The #ESCCongress 2024 was formidable. I am happy to post this visual report, seen through the eyes of the #escpatientforum. What do patients actually do at a congress of the European Society of Cardiology? 🤝 In the ESC patient forum, we connect and learn from each other’s incredible stories, creating a single, shared narrative that we, as heart patients, carry forward to contribute to a better world for all of us, for our children, and for our grandchildren in the future. 💓 We network with cardiologists, other patients, and a vast amount of people who are part of the immensely large cardiology ecosystem. 💡 And last but not least: we actively participate in specific themes, working groups, and the very important "Guideline Task Forces" in different areas of cardiology: the standards for cardiological treatments, so to speak. By being allowed to express our patient perspectives on stage or in these working groups, we consistently bring a strong human-focused approach to the otherwise very technical, often high-tech world of cardiology. As patients, we increasingly feel being an essential a part of the cardiology ecosystem. What is this all about, I hear you think? Well, it's actually about all sorts of aspects related to care for heart and blood vessels. Prevention of heart failure, blood pressure monitoring, cardiovascular surgery, heart diseases, prosthetics, implants and transplants, cardiological issues combined with cancer, strokes, obesity, and many other diseases, digital tools and often handy devices that can make life easier in the hospital but also at home, apps, data and AI, and - literally - thousands of other matters related to cardiology. #ESCCongress 2024 in London: you were fantastic ! See you next year in Madrid ! #patientcenteredcare #lifeisgreat

52

1 commentaire